Innospec Inc. — Q3 2013 Form 10-Q
Business context and reporting period. Unaudited results cover the three and nine months ended September 30, 2013, compared with the corresponding 2012 periods. Innospec reports Fuel Specialties, Performance Chemicals and Octane Additives. The company describes the first two as growth-oriented businesses and Octane Additives as exposed to volatile, generally declining demand. Amounts are in U.S. dollars unless noted.
Key financial metrics
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Net sales | $192.8m | $183.4m | $577.2m | $562.7m |
| Gross profit | $57.4m | $50.7m | $180.6m | $171.4m |
| Gross margin | 29.8% | 27.6% | 31.3% | 30.5% |
| Operating income | $19.5m | $17.3m | $64.0m | $72.6m |
| Income before tax | $18.3m | $17.0m | $62.1m | $68.5m |
| Net income | $14.0m | $15.5m | $49.1m | $55.6m |
| Diluted EPS | $0.58 | $0.65 | $2.04 | $2.33 |
- Q3 sales rose 5% and gross profit rose 13%, but net income declined about 10%, reflecting higher operating expenses and tax expense. Q3 operating expenses were $37.9m versus $33.4m.
- Nine-month sales increased 3%, while operating income fell 12% and net income fell 12%. Operating expenses rose to $116.6m from $98.8m, including higher segment and corporate costs, pension charges, acquisition-related spending and research and development.
- Segment sales, Q3 / nine months: Fuel Specialties $137.4m / $403.6m; Performance Chemicals $47.9m / $140.2m; Octane Additives $7.5m / $33.4m. Against prior year, Q3 Fuel Specialties grew 8%, Performance Chemicals 2%, while Octane Additives declined 22%; nine-month changes were +8%, +1% and -36%, respectively.
- Cash from operations was $31.8m for nine months, versus $59.0m in 2012. The filing attributes the decrease to higher working-capital needs, lower net income and movements in accrued income taxes. Inventory increased $29.0m; management said the company built strategic stock ahead of an anticipated increase in fourth-quarter sales.
- At September 30, cash and cash equivalents were $53.9m and short-term investments were $6.4m. Total debt was $93.0m ($88.0m on the revolving facility and a $5.0m promissory note), implying net debt of approximately $32.7m after cash and short-term investments. Shareholders’ equity was $376.0m.
- Working capital was $209.4m; the company’s non-GAAP adjusted working capital was $147.4m, up from $128.7m at year-end 2012. Current assets were $363.2m and current liabilities $153.8m.
Material changes, outlook and management commentary
- Fuel Specialties benefited from stronger demand, improved mix in EMEA and Avtel, and the Strata acquisition; Americas mix was weaker and ASPAC volume declined in Q3. Performance Chemicals had mixed regional demand and pricing, with acquisition contributions from Chemsil and Chemtec. Octane Additives’ lower sales reflected shipment timing and declining demand from major customers.
- On August 30, Innospec acquired Chemsil Silicones and Chemtec Chemical for $51.2m cash plus $6.2m in stock; the preliminary net purchase price was $57.4m. The businesses have combined annual sales of about $40m and contributed $3.1m sales and $0.2m net income after acquisition through September 30. Purchase accounting remained provisional.
- On November 4, after quarter-end, the company acquired the Bachman Group Companies for $45m cash and approximately $15m in shares. The oilfield chemicals and services businesses have annual sales of about $80m. The filing says valuation and pro forma information were not yet available.
- The revolving credit facility was amended in August: capacity increased from $100m to $150m, with an option to request up to a further $50m in commitments; the facility runs through December 2016.
- No specific numerical earnings or sales guidance is provided in the supplied filing text. Management’s stated near-term sales-related commentary includes the inventory build in preparation for anticipated higher fourth-quarter sales; the filing cautions that interim results are not necessarily indicative of full-year results.
- Environmental remediation and closure provisions totaled $31.1m, principally related to the Ellesmere Port, U.K. site. Management noted uncertainty around the timing and probability of some future costs. A U.K. claim by JAG seeks up to $42.3m; Innospec says it considers the allegations without merit and intends to defend the case. Separately, $5.0m of guarantees for affiliated companies were contingent and unrecognized.
- Unrecognized tax benefits, including interest and penalties, totaled $12.5m; tax audits were ongoing in the U.S., Germany and U.K. Management did not expect audit adjustments to materially change the company’s financial position. The company intends to reinvest overseas earnings; repatriation could result in additional U.S. tax.
- The company reported a $1.0m nine-month goodwill impairment in Octane Additives. Its Q3 GAAP effective tax rate was 23.5%, versus 8.8% a year earlier; nine-month rates were 20.9% and 18.8%. Management cited geographic profit mix and U.K. deferred-tax remeasurement effects.
Most important facts for investors to verify
- Whether the fourth-quarter sales anticipated by management materialize, and whether the elevated inventory converts to sales without increased discounting or write-downs.
- How effectively the Chemsil/Chemtec and Bachman acquisitions integrate, including realized growth, margins, purchase-price allocations, amortization and financing impact.
- The sustainability of Fuel Specialties’ margin gains and the trajectory of Performance Chemicals, alongside continued demand and shipment declines in Octane Additives.
- Operating cash generation and working-capital trends, particularly inventory, given the sharp reduction in year-to-date operating cash flow.
- Debt utilization, liquidity and any additional facility commitments; $49.0m of cash was held by non-U.S. subsidiaries, and management did not expect repatriation in the foreseeable future.
- Developments in the JAG litigation, environmental remediation estimates, tax audits and other contingencies; the filing does not quantify a likely outcome for the JAG claim.